Publications:  Dr Upkar Gill

Gill US, McCarthy NE(2019). CD4 T cells in hepatitis B virus: "You don't have to be cytotoxic to work here and help". Journal of Hepatology

Gill US, Golden-Mason L(2019). HCMV jogs the ‘memory’ of NK cells in HBV. Journal of Hepatology vol. 70, (3) 343-345.

Schurich A, Pallett LJ, Jajbhay D, Wijngaarden J, Otano I, GIll US, Hansi N, Kennedy PT et al.(2016). Distinct metabolic requirements of exhausted and functional virus-specific CD8 T cells in the same host. Cell Reports vol. 16, (5) 1243-1252.

Stegmann KA, Robertson F, Hansi N, Gill U, Pallant C, Christophides T, Pallett LJ, Peppa D et al.(2016). CXCR6 marks a novel subset of T-betloEomeshi natural killer cells residing in human liver. Scientific Reports vol. 6, 26157-26157.

Rivino L, Van Den Berg M, Gill US, Le Bert N, Koh S, Hansi NK, Newell E, Foster GR et al. (2015). CHARACTERISATION OF THE IMMUNE PROFILE IN CHRONIC HEPATITIS B PATIENTS FOLLOWING NUCLEOS (T)IDE DISCONTINUATION BY CYTOF MASS CYTOMETRY. GUT. vol. 64, A106-A107.

Hansi N, Gill US, Banerjee M, Naik S, Tong W, Foster GR, Carey I, Kennedy PT (2015). DEFINING THE LOW-RISK INACTIVE CARRIER IN CHRONIC HEPATITIS B WITH QHBSAG: DO THE SAME RULES APPLY IN CHILDREN AND YOUNG ADULTS?. GUT. vol. 64, A108-A109.

Gill US, Peppa D, Micco L, Singh HD, Foster GR, Maini MK, Kennedy PTF (2015). FUNCTIONAL IMMUNE RESTORATION CORRELATES WITH HBSAG DECLINE AND MAY PREDICT TREATMENT RESPONSE ON SEQUENTIAL NUC THERAPY IN CHB. GUT. vol. 64, A113-A113.

Hansi N, Gill US, Banerjee M, Naik S, Tong W, Foster GR, Carey I, Kennedy PT (2015). IDENTIFYING TRUE IMMUNE-TOLERANT DISEASE IN CHILDREN AND YOUNG ADULTS WITH CHB USING QUANTIFIED HEPATITIS B SURFACE ANTIGEN LEVELS. GUT. vol. 64, A108-A108.

Gill US, Hansi NK, Payaniandy L, Schulz J, Payaniandy D, Alazawi W, Dearden J, Kallis YN et al. (2015). SEQUENTIAL NUC THERAPY FOLLOWING PEGYLATED INTERFERON PROVIDES A GREATER DECLINE IN HBSAG AND POTENTIALLY OFFERS A TREATMENT ADVANTAGE OVER CURRENT THERAPIES. GUT. vol. 64, A113-A113.

KENNEDY PATRICK(2015). Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. Nature Medicine vol. 21, 591-600.

Rivino L, Van Den Berg M, Le Bert N, Koh S, Gill US, Hansi NK, Foster GR, Bertoletti A et al. (2015). CHARACTERISATION OF THE IMMUNE PROFILES OF CHRONIC HEPATITIS B PATIENTS FOLLOWING NUC DISCONTINUATION BY CyTOF MASS CYTOMETRY. JOURNAL OF HEPATOLOGY. vol. 62, S491-S491.

Gill US, Peppa D, Micco L, Singh HD, Foster GR, Maini MK, Kennedy PT (2015). FUNCTIONAL IMMUNE RESTORATION CORRELATES WITH HBsAg DECLINE AND MAY PREDICT TREATMENT RESPONSE ON SEQUENTIAL NUC THERAPY IN CHRONIC HEPATITIS B. JOURNAL OF HEPATOLOGY. vol. 62, S496-S496.

Huang W-C, Peppa D, Easom N, Tang X-Z, Singh H, Fusai G, Rosenberg W, Ghosh I et al. (2015). NKG2D-DEPENDENT CROSS-TALK BETWEEN NK CELLS AND CD4 T CELLS IN CHRONIC HEPATITIS B. JOURNAL OF HEPATOLOGY. vol. 62, S493-S493.

Pallett L, Gill U, Jover-Cobos M, Schurich A, Singh K, Thomas N, Das A, Chen A et al.(2014). Arginase-dependent metabolic regulation of hepatic immunopathology by myeloid-derived suppressor cells. IMMUNOLOGY vol. 143, 154-154.

GILL US, Zissimopoulos A, Al-Shamma S, Burke K, McPhail MJ, Barr DA, Yallis YN, Marley RT et al.(2014). Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?. The Journal of Infectious Diseases vol. 211, (3) 374-382.

Kennedy PTF, Gill US, Bertoletti A, Mason WS (2014). CLONAL HEPATOCYTE REPOPULATION IN THE YOUNG ADULT HBV INFECTED LIVER CHALLENGES THE CONCEPT OF A GENERIC IMMUNE TOLERANT DISEASE PHASE. JOURNAL OF HEPATOLOGY. vol. 60, S43-S43.

Lubowiecki M, Pallmer K, Jajbhay D, Pallett LJ, Gill U, Kennedy PT, Maini M, Schurich A (2014). CO-INHIBITORY RECEPTOR LAG-3 POSITIVE CD8 T CELLS PRODUCE IMMUNOSUPPRESSIVE TGF-beta IN CHRONIC HBV. JOURNAL OF HEPATOLOGY. vol. 60, S118-S119.

Vergis N, Khamri W, Atkinson S, Tidswell R, Gill U, Ryan J, Bernsmeier C, Triantafyllou E et al. (2014). MONOCYTE OXIDATIVE BURST DEFECT PREDICTS RISK OF INFECTION IN ALCOHOLIC HEPATITIS. JOURNAL OF HEPATOLOGY. vol. 60, S168-S168.

Pallett LJ, Haniffa M, Schurich A, Gill U, Davies N, Jover-Cobos M, Das A, Gilson R et al. (2014). MYELOID-DERIVED SUPPRESSOR CELLS MEDIATE IMMUNOTOLERANCE IN CHRONIC HEPATITIS B (CHB) THROUGH ARGININE DEPRIVATION. JOURNAL OF HEPATOLOGY. vol. 60, S109-S109.

Gill US, Peppa D, Micco L, Singh HD, Foster GR, Maini MK, Kennedy PTF (2014). SEQUENTIAL NUC THERAPY FOLLOWING PEGYLATED INTERFERON-ALPHA EXPOSURE RESTORES INNATE IMMUNE RESPONSES CONFERRING A TREATMENT ADVANTAGE OVER NUC MONOTHERAPY IN CHRONIC HEPATITIS B. JOURNAL OF HEPATOLOGY. vol. 60, S116-S116.

Huang W-C, Peppa D, Easom N, Tan X-Z, Chang C, Trowsdale J, Gill U, Kennedy P et al. (2014). THE EXPRESSION OF NKG2D-LIGANDS BY ACTIVATED CD4 T CELLS RENDERS THEM SUSCEPTIBLE TO NK CELL REGULATION IN CHRONIC HEPATITIS B (CHB). JOURNAL OF HEPATOLOGY. vol. 60, S111-S111.

Gill US, Peppa D, Singh HD, Micco L, Foster GR, Maini MK, Kennedy PT (2014). Functional innate immune responses are restored with sequential NUC therapy following Pegylated Interferon-Alpha exposure and not with NUC monotherapy in Chronic Hepatitis B. HEPATOLOGY. vol. 60, 1020A-1021A.

Hansi NK, Gill US, Banerjee A, Surendraraj N, Patel C, Naik S, Foster GR, Kennedy PT (2014). High levels of Hepatitis B surface antigen (HBsAg) can exclude significant fibrosis and distinguishes true 'immune-tolerance' in children and young adults with Chronic Hepatitis B. HEPATOLOGY. vol. 60, 985A-986A.

Jo J, Tan AT, Ussher JE, Sandalova E, Tang XZ, Tan-Garcia A, To N, Hong M et al.(2014). Toll-Like Receptor 8 Agonist and Bacteria Trigger Potent Activation of Innate Immune Cells in Human Liver. PLoS Pathogens vol. 10, (6)

Lubowiecki M, Pallmer K, Jajbhay D, Pallett LJ, Gill U, Kennedy PT, Maini MK, Schurich A (2013). Co-inhibitory receptor LAG-3 positive CD8 T cells produce immunosuppressive TGF-beta in chronic HBV. IMMUNOLOGY. vol. 140, 145-145.

Pallett LJ, Haniffa M, Jover-Cobos M, Schurich A, Das A, Gill U, Davies N, Ghosh I et al. (2013). Expansion of arginase-expressing myeloid-derived suppressor cells in hepatotropic viral infections. IMMUNOLOGY. vol. 140, 97-97.

Gill US, Zissimopoulos A, Al-shamma S, Burke K, McPhail M, Barr D, Ross V, Kallis Y et al. (2013). FRAX SCORE IN THE ASSESSMENT OF BONE MINERAL DENSITY CHANGES IN TENOFOVIR TREATED CHRONIC HEPATITIS B PATIENTS. GUT. vol. 62, A190-A190.

Gill US, Payaniandy L, Schulz J, Payaniandy D, Ross V, Kallis Y, Kooner P, Marley R et al. (2013). SEQUENTIAL ORAL ANTI-VIRAL THERAPY FOLLOWING PEGYLATED-INTERFERON-ALPHA FAILURE SIGNIFICANTLY INCREASES HBSAG DECLINE. GUT. vol. 62, A189-A190.

Schurich A, Pallett LJ, Lubowiecki M, Singh HD, Gill US, Kennedy PT, Nastouli E, Tanwar S et al.(2013). The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T Cells. PLoS Pathogens vol. 9, (3)

Gill US, Payaniandy L, Payaniandy D, Schulz J, Ross VA, Kallis YN, Kooner P, Marley RTC et al. (2013). INDUCTION MAINTENANCE THERAPY IN CHRONIC HEPATITIS B; STEP-DOWN FROM COMBINATION LAMIVUDINE AND TENOFOVIR TO LAMIVUDINE MONOTHERAPY - A POTENTIAL NEW TREATMENT STRATEGY. JOURNAL OF HEPATOLOGY. vol. 58, S302-S302.

Chen A, Schurich A, Aleong J-AC, Trivedi K, Gill U, Peppa D, Kennedy P, Bertoletti A et al. (2013). PROBING HEPATIC ANTIGEN PRESENTATION IN PATIENTS WITH CHRONIC HBV INFECTION. JOURNAL OF HEPATOLOGY. vol. 58, S136-S136.

Peppa D, Gil US, Reynolds G, Easom NJW, Pallett LJ, Schurich A, Micco L, Nebbia G et al.(2013). Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. Journal of Experimental Medicine vol. 210, (1) 99-114.

Das A, Ellis G, Pallant C, Lopes AR, Khanna P, Peppa D, Chen A, Blair P et al.(2012). IL-10-Producing Regulatory B Cells in the Pathogenesis of Chronic Hepatitis B Virus Infection. JOURNAL OF IMMUNOLOGY vol. 189, (8) 3925-3935.

Patel C, Gill U, Alazawi W, Shaw P, Alstead EM, Kallis Y, Kooner P, Marley R et al. (2012). Benchmarking disease activity and progression in Chronic Hepatitis B infected young adults. HEPATOLOGY. vol. 56, 362A-362A.

Gill U, Zissimopoulos A, Al-Shamma S, Burke KB, Ross VA, Kallis Y, Kooner P, Marley R et al. (2012). FRAX score in the assessment of Bone Mineral Density changes in Tenofovir treated Chronic Hepatitis B patients: comparison with bone biochemistry and DEXA scanning. HEPATOLOGY. vol. 56, 201A-201A.

Kennedy PTF, Sandalova E, Jo J, Gill U, Ushiro-Lumb I, Tan AT, Naik S, Foster GR et al.(2012). Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology vol. 143, (3) 637-645.

Gill US, Payaniandy L, Schulz J, Ross V, Kallis Y, Kooner P, Marley R, Ushiro-Lumb I et al.(2012). CAN A 3-MONTH "STOPPING RULE" FOR PEGYLATED-INTERFERON-alpha BE APPLIED TO A UK POPULATION OF CHRONIC HEPATITIS B INFECTED PATIENTS OF MIXED GENOTYPE?. GUT vol. 61, A145-A145.

Patel C, Gill US, Alazawi W, Shaw P, Alstead E, Kallis Y, Kooner P, Marley R et al.(2012). EVALUATION OF LIVER FIBROSIS IN YOUNG ADULT PATIENTS WITH CHRONIC HEPATITIS B VIRUS. GUT vol. 61, A133-A133.

Gill US, Payaniandy L, Payaniandy D, Schulz J, Ross V, Kallis Y, Kooner P, Marley R et al.(2012). INDUCTION MAINTENANCE TREATMENT IN CHRONIC HEPATITIS B; STEP-DOWN FROM TENOFOVIR AND LAMIVUDINE TO LAMIVUDINE MONOTHERAPY IS EFFECTIVE. GUT vol. 61, A145-A145.

Gill US, Papadaki M, Peppa D, Micco L, Li L, Ushiro-Lumb I, Foster GR, Maini MK et al.(2012). MAXIMAL BOOSTING OF INNATE IMMUNITY DURING PEGYLATED INTERFERON-alpha THERAPY IS REACHED AT 48 WEEKS IN E-ANTIGEN POSITIVE CHRONIC HEPATITIS B. GUT vol. 61, A145-A146.

Gill US, Papadaki M, Peppa D, Micco L, Li L, Ushiro-Lumb I, Foster GR, Maini MK et al. (2012). MAXIMAL BOOSTING OF INNATE IMMUNITY DURING PEGYLATED INTERFERON-APLHA THERAPY IS REACHED AT 48 WEEKS IN E-ANTIGEN POSITIVE CHRONIC HEPATITIS B. JOURNAL OF HEPATOLOGY. vol. 56, S175-S175.

Peppa D, Gill U, Micco L, Schurich A, Nebbia G, Singh H, Rosenberg W, Gilson R et al. (2011). Susceptibility of T cells to death ligand-mediated deletion in the liver of chronic hepatitis B virus (CHB) infected patients. IMMUNOLOGY. vol. 135, 60-60.

Gill U, Al-Shamma S, Burke KB, Ross VA, Marley R, Kooner P, Foster GR, Kennedy PT (2011). BONE MINERAL DENSITY LOSS IN TENOFOVIR TREATED CHRONIC HEPATITIS B VIRUS (HBV) PATIENTS IS A CONSEQUENCE OF VITAMIN D DEFICIENCY AND NOT TENOFOVIR THERAPY. HEPATOLOGY. vol. 54, 1012A-1012A.

Kennedy PT, Sandalova E, Jo J, Gill U, Li L, Ushiro-Lumb I, Naik S, Foster GR et al. (2011). IMMUNOLOGICAL ANALYSIS AND CLINICAL PROFILE OF CHRONIC HEPATITIS B VIRUS (HBV) INFECTION IN THE YOUNGER PATIENT. HEPATOLOGY. vol. 54, 1092A-1093A.

Gill US, Al-Shamma S, Burke K, Ross V, Marley RTC, Kooner P, Foster GR, Kennedy PTF(2011). BONE MINERAL DENSITY LOSS IN TENOFOVIR TREATED CHRONIC HEPATITIS B VIRUS (HBV) PATIENTS IS A CONSEQUENCE OF VITAMIN D DEFICIENCY AND NOT TENOFOVIR THERAPY. GUT vol. 60, A28-A28.

Kennedy PTF, Sandalova E, Jo J, Gill US, Li L, Ushiro-Lumb I, Naik S, Foster GR et al.(2011). IMMUNOLOGICAL ANALYSIS AND CLINICAL PROFILE OF CHRONIC HEPATITIS B VIRUS (HBV) INFECTION IN THE YOUNGER PATIENT. GUT vol. 60, A29-A29.

Patel C, Gill US, Glyn F, Naik S, Foster GR, Kennedy PTF (2011). CHRONIC HBV INFECTION: ASSESSMENT AND MANAGEMENT OF DISEASE IN A YOUNG ADULT CLINIC. GUT. vol. 60,

Glyn F, Gill US, Alazawi W, Ross V, Kooner P, Marley R, Foster GR, Kennedy PTF (2011). EFFICACY OF COMBINATION TENOFOVIR PLUS LAMIVUDINE VERSUS TENOFOVIR MONOTHERAPY IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS. GUT. vol. 60, A231-A231.

Gill US, Al-Shamma S, Burke K, Ross V, Marley R, Kooner P, Foster GR, Kennedy PTF (2011). FACTORS DETERMINING BONE MINERAL DENSITY LOSS IN CHRONIC HEPATITIS B PATIENTS: IS TENOFOVIR DISOPROXIL FUMARATE THE MAIN CULPRIT?. GUT. vol. 60,

Gill U, Micco L, Li L, Peppa D, Ushiro-Lumb I, Foster GR, Maini MK, Kennedy PTF (2011). PEGYLATED INTERFERON A MODULATES INNATE IMMUNITY IN EAG POSITIVE CHRONIC HEPATITIS B AND DETERMINES CHANGES IN HBSAG QUANTIFICATION. GUT. vol. 60, A232-A232.

Gunawan A, Gill US, Glyn F, Kooner P, Marley R, Ushiro-Lumb I, Foster GR, Kennedy PTF (2011). UTILITY OF HBSAG QUANTIFICATION IN DEVELOPING AN INDIVIDUALISED APPROACH TO THE MANAGEMENT OF CHRONIC HEPATITIS B VIRUS IN CLINICAL PRACTICE. GUT. vol. 60,

Gill US, Al-Shamma S, Burke K, Ross V, Kooner P, Marley R, Foster GR, Kennedy PTF (2011). FACTORS DETERMINING BONE MINERAL DENSITY LOSS IN CHRONIC HEPATITIS B PATIENTS: IS TENOFOVIR DISOPROXIL FUMARATE THE MAIN CULPRIT?. JOURNAL OF HEPATOLOGY. vol. 54, S286-S286.

Gill US, Micco L, Li L, Peppa D, Ushiro-Lumb I, Foster GR, Maini MK, Kennedy PTF (2011). PEGYLATED INTERFERON ALPHA MODULATES INNATE IMMUNITY IN EAG POSITIVE CHRONIC HEPATITIS B AND DETERMINES CHANGES IN HBSAG QUANTIFICATION. JOURNAL OF HEPATOLOGY. vol. 54, S32-S32.